{"schema_version":"secwatch.filing_event.v1","accession":"0001824293-25-000126","form_type":"8-K","ticker":"GRI","cik":"0001824293","company_name":"GRI Bio, Inc.","filed_at":"2025-08-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.157453+00:00","generated_at":"2026-05-17T11:10:54.297087+00:00","sec_items":["7.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"GRI Bio files corporate presentation with no material new disclosures","bullets":["Furnished a corporate presentation dated August 20, 2025 under Regulation FD.","Presentation provides an overview of GRI Bio's approach to inflammatory diseases.","No specific financial results, guidance, or material operational updates were disclosed.","The filing is made under Item 7.01 and is not deemed filed for SEC purposes.","Ticker: GRI; stock trades on Nasdaq Capital Market."],"urls":{"canonical":"https://secwatch.observer/filing/0001824293-25-000126","json":"https://secwatch.observer/filing/0001824293-25-000126.json","markdown":"https://secwatch.observer/filing/0001824293-25-000126.md","text":"https://secwatch.observer/filing/0001824293-25-000126.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824293/000182429325000126/0001824293-25-000126-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824293/000182429325000126/val-20250820.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T11:10:54.297087+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}